Sales 2024 * | 76.08M 103M | Sales 2025 * | 68.35M 92.93M | Capitalization | 336M 457M |
---|---|---|---|---|---|
Net income 2024 * | -155M -211M | Net income 2025 * | -170M -231M | EV / Sales 2024 * | 2.91 x |
Net cash position 2024 * | 115M 156M | Net cash position 2025 * | 281M 383M | EV / Sales 2025 * | 0.8 x |
P/E ratio 2024 * |
-2.27
x | P/E ratio 2025 * |
-2.58
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.63% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |